• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用简单、明确的细菌疗法靶向修复肠道微生物群可解决小鼠复发性艰难梭菌病。

Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice.

机构信息

Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

出版信息

PLoS Pathog. 2012;8(10):e1002995. doi: 10.1371/journal.ppat.1002995. Epub 2012 Oct 25.

DOI:10.1371/journal.ppat.1002995
PMID:23133377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3486913/
Abstract

Relapsing C. difficile disease in humans is linked to a pathological imbalance within the intestinal microbiota, termed dysbiosis, which remains poorly understood. We show that mice infected with epidemic C. difficile (genotype 027/BI) develop highly contagious, chronic intestinal disease and persistent dysbiosis characterized by a distinct, simplified microbiota containing opportunistic pathogens and altered metabolite production. Chronic C. difficile 027/BI infection was refractory to vancomycin treatment leading to relapsing disease. In contrast, treatment of C. difficile 027/BI infected mice with feces from healthy mice rapidly restored a diverse, healthy microbiota and resolved C. difficile disease and contagiousness. We used this model to identify a simple mixture of six phylogenetically diverse intestinal bacteria, including novel species, which can re-establish a health-associated microbiota and clear C. difficile 027/BI infection from mice. Thus, targeting a dysbiotic microbiota with a defined mixture of phylogenetically diverse bacteria can trigger major shifts in the microbial community structure that displaces C. difficile and, as a result, resolves disease and contagiousness. Further, we demonstrate a rational approach to harness the therapeutic potential of health-associated microbial communities to treat C. difficile disease and potentially other forms of intestinal dysbiosis.

摘要

人类复发性艰难梭菌病与肠道微生物群落的病理性失衡有关,这种失衡被称为“菌群失调”,但目前对此仍知之甚少。我们发现,感染流行型艰难梭菌(基因型 027/BI)的小鼠会患上高度传染性的慢性肠道疾病和持续性菌群失调,其特征是特定的、简化的微生物群落中含有机会性病原体,并改变了代谢产物的产生。慢性艰难梭菌 027/BI 感染对万古霉素治疗有抗药性,导致疾病复发。相比之下,用健康小鼠的粪便治疗感染艰难梭菌 027/BI 的小鼠,可以迅速恢复多样化的健康微生物群落,并解决艰难梭菌病和传染性问题。我们利用该模型鉴定出了一种简单的六种具有不同进化背景的肠道细菌混合物,其中包括新型细菌,它可以重建与健康相关的微生物群,并从小鼠体内清除艰难梭菌 027/BI 感染。因此,用具有不同进化背景的特定混合菌群来靶向失调的微生物群,可以引发微生物群落结构的重大变化,从而取代艰难梭菌,并由此解决疾病和传染性问题。此外,我们还证明了一种合理的方法,可以利用与健康相关的微生物群落的治疗潜力来治疗艰难梭菌病和可能的其他形式的肠道菌群失调。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/c4fbea693d5d/ppat.1002995.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/d43c7634b7f2/ppat.1002995.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/5c8568cc90e1/ppat.1002995.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/3c98b54b44a9/ppat.1002995.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/881f174b4808/ppat.1002995.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/972378385c56/ppat.1002995.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/c4fbea693d5d/ppat.1002995.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/d43c7634b7f2/ppat.1002995.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/5c8568cc90e1/ppat.1002995.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/3c98b54b44a9/ppat.1002995.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/881f174b4808/ppat.1002995.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/972378385c56/ppat.1002995.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4621/3486913/c4fbea693d5d/ppat.1002995.g006.jpg

相似文献

1
Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice.用简单、明确的细菌疗法靶向修复肠道微生物群可解决小鼠复发性艰难梭菌病。
PLoS Pathog. 2012;8(10):e1002995. doi: 10.1371/journal.ppat.1002995. Epub 2012 Oct 25.
2
Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.肠道微生物群在抵抗艰难梭菌定植中的作用。
Gastroenterology. 2014 May;146(6):1547-53. doi: 10.1053/j.gastro.2014.01.059. Epub 2014 Feb 4.
3
Infection: treating recurrent C. difficile infection-the challenge continues.感染:治疗艰难梭菌反复感染——挑战仍在继续。
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):10-1. doi: 10.1038/nrgastro.2012.240. Epub 2012 Dec 4.
4
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.万古霉素治疗与小鼠肠道组织损伤延迟、梭状芽孢杆菌过度生长和艰难梭菌感染复发的关系。
Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. doi: 10.1128/AAC.00877-12. Epub 2012 Nov 12.
5
Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.复发性艰难梭菌感染:肠道微生物群的重要性。
World J Gastroenterol. 2014 Jun 21;20(23):7416-23. doi: 10.3748/wjg.v20.i23.7416.
6
From stool transplants to next-generation microbiota therapeutics.从粪便移植到下一代微生物组治疗。
Gastroenterology. 2014 May;146(6):1573-1582. doi: 10.1053/j.gastro.2014.01.004. Epub 2014 Jan 8.
7
Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.肠道微生物组的改变:粪便微生物群移植和益生菌治疗艰难梭菌感染及其他疾病。
Expert Rev Gastroenterol Hepatol. 2013 Sep;7(7):615-28. doi: 10.1586/17474124.2013.832501.
8
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.微生物群移植可恢复复发性艰难梭菌感染患者的正常粪便胆汁酸组成。
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9. doi: 10.1152/ajpgi.00282.2013. Epub 2013 Nov 27.
9
A review of the economics of treating Clostridium difficile infection.艰难梭菌感染治疗的经济学综述。
Pharmacoeconomics. 2014 Jul;32(7):639-50. doi: 10.1007/s40273-014-0161-y.
10
Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology.粪便微生物群移植作为一种修复肠道微生物生态紊乱的方法的出现。
Immunol Lett. 2014 Dec;162(2 Pt A):77-81. doi: 10.1016/j.imlet.2014.07.016. Epub 2014 Aug 10.

引用本文的文献

1
Friend or foe: the gut microbiota as a modulator of disease trajectory in trauma, surgery, and critical illness.敌友难辨:肠道微生物群作为创伤、手术及危重症疾病发展轨迹的调节因子
Gut Microbes. 2025 Dec;17(1):2552346. doi: 10.1080/19490976.2025.2552346. Epub 2025 Aug 29.
2
Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions in infection (CDI), asymptomatic carriage and non-CDI diarrhea.宏基因组分析揭示了感染性(艰难梭菌感染)、无症状携带和非艰难梭菌感染性腹泻中具有多样化功能的肠道微生物群特征的不同模式。
Gut Microbes. 2025 Dec;17(1):2505269. doi: 10.1080/19490976.2025.2505269. Epub 2025 May 14.
3

本文引用的文献

1
The Clostridium difficile spo0A gene is a persistence and transmission factor.艰难梭菌 spo0A 基因是一个持续存在和传播的因素。
Infect Immun. 2012 Aug;80(8):2704-11. doi: 10.1128/IAI.00147-12. Epub 2012 May 21.
2
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.由流行的艰难梭菌 BI 菌株引起的艰难梭菌感染的治愈率降低和复发率增加。
Clin Infect Dis. 2012 Aug;55(3):351-7. doi: 10.1093/cid/cis430. Epub 2012 Apr 20.
3
Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing.
Enabling next-generation anaerobic cultivation through biotechnology to advance functional microbiome research.
通过生物技术实现下一代厌氧培养,以推进功能性微生物组研究。
Nat Biotechnol. 2025 Apr 29. doi: 10.1038/s41587-025-02660-6.
4
Causal role of the gut microbiome in certain human diseases: a narrative review.肠道微生物群在某些人类疾病中的因果作用:一项叙述性综述。
eGastroenterology. 2024 Sep 10;2(3):e100086. doi: 10.1136/egastro-2024-100086. eCollection 2024 Sep.
5
The Efficacy of Fecal Microbiota Transplantation in Mouse Models Infected with from the Perspective of Metabolic Profiling: A Systematic Review.从代谢谱角度看粪便微生物群移植在感染小鼠模型中的疗效:一项系统评价
Metabolites. 2024 Dec 3;14(12):677. doi: 10.3390/metabo14120677.
6
Type III Secretion System in Intestinal Pathogens and Metabolic Diseases.肠道病原体与代谢疾病中的 III 型分泌系统。
J Diabetes Res. 2024 Nov 6;2024:4864639. doi: 10.1155/2024/4864639. eCollection 2024.
7
Gut Microbial and Metabolic Features Associated With Infection Recurrence in Children.与儿童感染复发相关的肠道微生物和代谢特征
Open Forum Infect Dis. 2024 Sep 3;11(9):ofae506. doi: 10.1093/ofid/ofae506. eCollection 2024 Sep.
8
The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities.肠道微生物群与肥胖相关代谢紊乱之间的复杂联系:机制与治疗机遇。
Heliyon. 2024 Sep 7;10(17):e37609. doi: 10.1016/j.heliyon.2024.e37609. eCollection 2024 Sep 15.
9
Identification of a family of peptidoglycan transpeptidases reveals that requires noncanonical cross-links for viability.鉴定出一组肽聚糖转肽酶家族,表明 需要非典型的交联来维持生存。
Proc Natl Acad Sci U S A. 2024 Aug 20;121(34):e2408540121. doi: 10.1073/pnas.2408540121. Epub 2024 Aug 16.
10
Beyond Antibiotics: Novel Approaches in the Treatment of Recurrent Infection.超越抗生素:复发性感染治疗的新方法
ACG Case Rep J. 2024 Jul 27;11(8):e01333. doi: 10.14309/crj.0000000000001333. eCollection 2024 Aug.
利用广泛的流行病学数据和分子分型技术对艰难梭菌医院病房传播进行特征描述。
PLoS Med. 2012 Feb;9(2):e1001172. doi: 10.1371/journal.pmed.1001172. Epub 2012 Feb 7.
4
Fecal microbiota transplantation and emerging applications.粪便微生物移植与新兴应用。
Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):88-96. doi: 10.1038/nrgastro.2011.244.
5
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.艰难梭菌毒素 A 和 B 的全身传播与动物模型中严重的、致命的疾病有关。
J Infect Dis. 2012 Feb 1;205(3):384-91. doi: 10.1093/infdis/jir748. Epub 2011 Dec 5.
6
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.接触抗生素后艰难梭菌感染风险增加的时间间隔。
J Antimicrob Chemother. 2012 Mar;67(3):742-8. doi: 10.1093/jac/dkr508. Epub 2011 Dec 6.
7
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.单次克林霉素给药导致肠道微生物群的深刻改变,从而使机体持续易患艰难梭菌诱导的结肠炎。
Infect Immun. 2012 Jan;80(1):62-73. doi: 10.1128/IAI.05496-11. Epub 2011 Oct 17.
8
Treating Clostridium difficile infection with fecal microbiota transplantation.粪便微生物移植治疗艰难梭菌感染。
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24.
9
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.艰难梭菌感染小鼠模型中微生物组动态与病原体动态的相互作用。
Gut Microbes. 2011 May-Jun;2(3):145-58. doi: 10.4161/gmic.2.3.16333. Epub 2011 May 1.
10
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.